达格列净在DAPA-HF研究中与利尿剂使用的关系
DAPA-HF试验事后分析按基线利尿剂剂量将4616例射血分数降低的心衰患者分为四组,比较达格列净与安慰剂的疗效。达格列净在各利尿剂亚组中降低主要复合终点风险的作用一致(交互P=0.61),症状改善和耐受性也一致,随访期间多数患者利尿剂剂量未变,两组平均剂量无差异。
要点
- 达格列净在无利尿剂及不同剂量利尿剂亚组中疗效一致
- 使用任何利尿剂患者的主要终点风险比为0.78(95%CI 0.68-0.90)
- 达格列净未显著改变随访期间的利尿剂剂量
核心结论
- 达格列净在DAPA-HF研究所检查的利尿剂亚组中疗效和安全性一致
- 达格列净降低主要复合终点风险不受基线利尿剂使用或剂量影响
研究设计与样本
- DAPA-HF试验的事后亚组分析,纳入4616例可分析的心衰伴射血分数降低患者
- 按基线利尿剂使用情况分为无利尿剂、呋塞米等效剂量<40mg/日、40mg/日、>40mg/日四个亚组
主要发现
- 736例(15.9%)未使用利尿剂,1311例(28.4%)使用<40mg/日,1365例(29.6%)使用40mg/日,1204例(26.1%)使用>40mg/日
- 达格列净对比安慰剂的主要终点风险比在各亚组分别为0.57(95%CI 0.36-0.92)、0.83(95%CI 0.63-1.10)、0.77(95%CI 0.60-0.99)、0.78(95%CI 0.63-0.97),交互P=0.61
- 使用任何利尿剂患者的主要终点风险比为0.78(95%CI 0.68-0.90)
- 症状改善和治疗耐受性在各利尿剂亚组中一致
- 随访期间多数患者利尿剂剂量未变,随机化后达格列净组与安慰剂组平均利尿剂剂量无差异
临床怎么用
- 达格列净可考虑用于心衰伴射血分数降低患者,无论其基线是否使用利尿剂或利尿剂剂量高低
- 使用达格列净时无需因基线利尿剂剂量而调整用药预期疗效
局限性
- 本研究为DAPA-HF试验的事后亚组分析
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction. We examined the efficacy and tolerability of dapagliflozin in relation to background diuretic treatment and change in diuretic therapy after randomization to dapagliflozin or placebo. METHODS: We examined the effects of study treatment in the following subgroups: no diuretic and diuretic dose equivalent to furosemide <40, 40, and >40 mg daily at baseline. We examined the primary composite end point of cardiovascular death or a worsening heart failure event and its components, all-cause death and symptoms. RESULTS: Of 4616 analyzable patients, 736 (15.9%) were on no diuretic, 1311 (28.4%) were on <40 mg, 1365 (29.6%) were on 40 mg, and 1204 (26.1%) were taking >40 mg. Compared with placebo, dapagliflozin reduced the risk of the primary end point across each of these subgroups: hazard ratios were 0.57 (95% CI, 0.36-0.92), 0.83 (95% CI, 0.63-1.10), 0.77 (95% CI, 0.60-0.99), and 0.78 (95% CI, 0.63-0.97), respectively (P for interaction=0.61). The hazard ratio in patients taking any diuretic was 0.78 (95% CI, 0.68-0.90). Improvements in symptoms and treatment toleration were consistent across the diuretic subgroups. Diuretic dose did not change in most patients during follow-up, and mean diuretic dose did not differ between the dapagliflozin and placebo groups after randomization. CONCLUSIONS: The efficacy and safety of dapagliflozin were consistent across the diuretic subgroups examined in DAPA-HF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03036124.
引用
- Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation. 2020. PMID: 32673497. doi:10.1161/CIRCULATIONAHA.120.047077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。